SAN FRANCISCO, CA--(Marketwired - December 13, 2013) - Kindred Biosciences, Inc. (Kindred Bio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the underwriters of its initial public offering exercised in full their option to purchase up to 1,125,000 additional shares of its common stock at the initial public offering price of $7.00 per share.
Including the exercise of the over-allotment, Kindred Bio has sold a total of 8,625,000 shares, which represents a total capital raise of $60,375,000 before deducting underwriting discounts and commissions and offering expenses payable by Kindred Bio.
BMO Capital Markets and Guggenheim Securities are acting as book-running managers for the offering. Roth Capital Partners is acting as co-manager for the offering.
The offering is being made only by means of a prospectus forming part of an effective registration statement. Copies of the prospectus relating to the offering, when available, may be obtained from BMO Capital Markets Corp. at 3 Times Square, 27th Floor, New York, NY 10036, Attention Equity Syndicate Department, by telephone at (800) 414-3627 or by email to firstname.lastname@example.org and from Guggenheim Securities, LLC at 330 Madison, 8th Floor, New York, NY 10017, Attention Equity Syndicate Department, by telephone at (212) 518-9349 or by email to GSEquityProspectusDelivery@guggenheimpartners.com.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.
About Kindred Biosciences
Kindred Biosciences is a development stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company's lead product candidates are CereKin for the treatment of osteoarthritis pain and inflammation in dogs, AtoKin for the treatment of atopic dermatitis in dogs, and SentiKin for the treatment of post-operative pain in dogs.